ILD Not Increased With MTX in Patients With Dermatomyositis

Treatment with methotrexate was not associated with an increased risk for interstitial lung disease (ILD) in patients with dermatomyositis.

Related Keywords

New York ,United States ,Jillt Shah , ,York University Langone Health ,National Institutes ,Health Sponsored All ,New York University Langone Health ,New York City ,Biologic Therapy ,Iologics ,Dermatomyositis ,Interstitial Lung Disease ,Lung ,Cancer ,Alignant Neoplasia ,Arcinoma ,Alignant Neoplasm ,Toxicology ,Toxicity ,Poisoning ,Toxins ,Antineoplastic Drug ,Nti Cancer Agents ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Monoclonal Antibody ,Etuximab ,Neoplasm ,Electronic Health Records ,